0K91 Stock Chart & Stats
€2.50
>-€0.01(-0.32%)
At close: 4:00 PM EDT
€2.50
>-€0.01(-0.32%)
Day’s Range― - ―
52-Week Range€1.62 - €16.80
Previous CloseN/A
Volume0.00
Average Volume (3M)611.00
Market Cap
€27.25M
Enterprise Value€13.44
Total Cash (Recent Filing)€9.73M
Total Debt (Recent Filing)€962.16K
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.65
Shares Outstanding8,087,479
10 Day Avg. Volume1,279
30 Day Avg. Volume611
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.47
Price to Sales (P/S)0.00
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.04Price Target Upside181.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lucid-MS Regulatory AdvancementFDA clearance moves Lucid-MS into a controlled Phase 2 study, materially advancing Quantum’s lead asset toward clinical validation. Its neuroprotective, non-immunomodulatory approach targets an area of high unmet need and could strengthen the company’s strategic position if clinical results support efficacy.
Improved Liquidity And Cost DisciplineThe stronger liquidity position and lower spending rate extend the company’s stated funding runway to at least October 2027 under its current burn rate. This gives Quantum more time to execute its Phase 2 program and reduces the immediate pressure to raise capital during development.
Relatively Modest LeverageRelatively low debt-to-equity limits fixed financial obligations compared with a more highly leveraged development-stage company. That provides some balance-sheet flexibility while Quantum funds clinical work, although the benefit is partly offset by its continuing losses and need for external financing.
Bears Say
Pre-revenue And Loss-making ModelQuantum has not yet established commercial revenue to offset research and corporate costs, while substantial losses continue across reported periods. The business therefore depends on successful clinical development and future financing rather than operating scale, making profitability highly dependent on pipeline execution.
Persistent Cash ConsumptionOngoing negative operating and free cash flow shows that Quantum’s current activities consume cash rather than generate it. Continued development spending will require the company to preserve its runway or obtain additional funding, leaving cash generation dependent on future product or partnership success.
Capital Erosion And Dilution RiskThe long-term decline in equity indicates that accumulated operating losses and financing activity have materially reduced the capital base supporting shareholders. This weakens financial resilience and increases the possibility that additional funding, potentially involving dilution, will be needed to advance the pipeline.
Quantum Biopharma News
0K91 FAQ
What was Quantum Biopharma’s price range in the past 12 months?
Quantum Biopharma lowest stock price was €1.62 and its highest was €16.80 in the past 12 months.
What is Quantum Biopharma’s market cap?
Quantum Biopharma’s market cap is €27.25M.
When is Quantum Biopharma’s upcoming earnings report date?
Quantum Biopharma’s upcoming earnings report date is Nov 06, 2026 which is in 36 days.
How were Quantum Biopharma’s earnings last quarter?
Quantum Biopharma released its earnings results on Aug 13, 2026. The company reported -€0.41 earnings per share for the quarter, missing the consensus estimate of -€0.366 by -€0.044.
Is Quantum Biopharma overvalued?
According to Wall Street analysts Quantum Biopharma’s price is currently Undervalued.
Does Quantum Biopharma pay dividends?
Quantum Biopharma does not currently pay dividends.
What is Quantum Biopharma’s EPS estimate?
Quantum Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quantum Biopharma have?
Quantum Biopharma has 8,087,479 shares outstanding.
What happened to Quantum Biopharma’s price movement after its last earnings report?
Quantum Biopharma reported an EPS of -€0.41 in its last earnings report, missing expectations of -€0.366. Following the earnings report the stock price went up 21.115%.
Which hedge fund is a major shareholder of Quantum Biopharma?
Currently, no hedge funds are holding shares in DE:0K91
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quantum Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.04 (181.51% Upside)
€7.04 (181.51% Upside)
Blogger Sentiment
Bearish
DE:0K91 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Quantum Biopharma
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
0K91 Stock 12 Month Forecast
Average Price Target
€7.04
▲(181.51% Upside)